Abstract
Brentuximab vedotin is active in primary effusion lymphoma, a rare CD30-positive lymphoma with an extremely poor prognosis.
MeSH terms
-
Antineoplastic Agents, Immunological / pharmacology
-
Brentuximab Vedotin / pharmacology*
-
Brentuximab Vedotin / therapeutic use
-
Humans
-
Ki-1 Antigen / metabolism
-
Lymphoma, AIDS-Related / drug therapy*
-
Lymphoma, Primary Effusion / drug therapy*
-
Male
-
Middle Aged
-
Treatment Outcome
Substances
-
Antineoplastic Agents, Immunological
-
Ki-1 Antigen
-
Brentuximab Vedotin